Theseus Pharmaceuticals Inc

NASDAQ THRX

Data sourced from

and

Daily

Download Data

Theseus Pharmaceuticals Inc Market Capitalization on February 23, 2024

Theseus Pharmaceuticals Inc Market Capitalization is NA on February 23, 2024, a NA change year over year. Market capitalization is a financial metric that represents the total value of a publicly traded company. It is calculated by multiplying the current share price of a company by the total number of outstanding shares. Market capitalization is used to assess the size and relative value of a company in the stock market. It provides investors with an idea of the company's overall worth and is often used as a basis for comparing companies within the same industry or sector. A higher market capitalization generally indicates a larger, more established company.

Theseus Pharmaceuticals Inc 52-week high Market Capitalization is USD 514.64 M on May 04, 2023, which is NA below the current Market Capitalization.
Theseus Pharmaceuticals Inc 52-week low Market Capitalization is USD 92.44 M on November 10, 2023, which is NA below the current Market Capitalization.
Theseus Pharmaceuticals Inc average Market Capitalization for the last 52 weeks is USD 246.81 M.

NASDAQ: THRX

Theseus Pharmaceuticals Inc

CEO	Dr. Iain D. Dukes D.Phil., DPHIL, M.A.
IPO Date	Oct. 7, 2021
Location	United States
Headquarters	245 Main Street, Cambridge, MA, United States, 02142
Employees	38
Sector	Healthcare
Industry	Biotechnology

Description

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC.

Key trends